Samir Vattompadam

Samir Vattompadam joined Kura in 2025 with more than 20 years of experience in the biotech and pharmaceutical industry including extensive leadership of global program teams that have driven the development and commercialization of 16 novel medicines and indications across 13 diseases, primarily in oncology and hematology. Most recently, he served as the Senior Vice President, Portfolio Strategy and Program Management at Vor Bio, leading Vor’s clinical-stage cell and genome-engineered therapies. Previously, Mr. Vattompadam was Vice President, EQRx, where he led program strategy teams for immuno-oncology assets from late-stage studies through to regulatory approval. Prior to that, he held positions of increasing responsibility across development, commercial, and medical affairs at Seagen (now Pfizer) and Roche in indications spanning malignant hematology and solid tumors. Mr. Vattompadam received his undergraduate and graduate degrees at McMaster University and holds a BS in Biology and a MS in Medical Sciences with specialty in Molecular Immunology, Virology, and Inflammation.